title: Antibiotic pharmacodynamics in cerebrospinal fluid.
abstract: The CSF half-lives of lipophilic agents, such as quinolones, are similar to those in serum and peak concentrations in CSF are achieved relatively quickly. In contrast, the pharmacokinetics of hydrophilic agents (beta-lactams and vancomycin) in CSF often differ from those in serum. In particular, the half-lives of these agents in CSF tend to be extended, and the time to achieve peak concentrations in CSF is delayed. Hydrophilic antibiotics, such as beta-lactams, penetrate poorly through the BBB, but CSF penetration is significantly increased in the presence of inflammation. In contrast, lipophilic antibiotics, such as quinolones, enter the CSF more efficiently and their penetration is not inflammation dependent. The pharmacodynamic properties of antibiotics in CSF are generally similar to those in other body sites; beta-lactam agents and vancomycin are time-dependent, whereas the quinolones and aminoglycosides are concentration-dependent. However, a notable difference from infections in other sites is that quinolones have a short PAE in CSF and need to continually exceed the MBC for maximal effectiveness. Thus, in CSF, quinolones demonstrate features of both concentration-dependency and time-dependency, evidence that the AUC/MBC is an important predictor of effectiveness. With the exception of quinolones, many antibiotics appear to have prolonged sub-MIC effects and longer half-lives in CSF than in serum, suggesting that dosing intervals longer than those used traditionally would be effective in meningitis. However, this requires clinical verification.
authors.affiliation: Department of Pediatrics, University of Texas, Southwestern Medical Center, Dallas, USA.
authors.forename: I
authors.initials: I
authors.lastname: Lutsar
authors.forename: G H
authors.initials: GH
authors.lastname: McCracken
authors.forename: I R
authors.initials: IR
authors.lastname: Friedland
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000134:cerebrospinal fluid* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001812:Blood-Brain Barrier; D002555:Cerebrospinal Fluid / Q000502:physiology; D004195:Disease Models, Animal; D006801:Humans; D016920:Meningitis, Bacterial / Q000134:cerebrospinal fluid* / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents